ciprofloxacin has been researched along with Corynebacterium Infections in 16 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Corynebacterium Infections: Infections with bacteria of the genus CORYNEBACTERIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 7.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| "In this study we aimed to determine the microorganisms found in perianal fistulas in Crohn's disease and whether treatment with ciprofloxacin affects these microorganisms." | 5.11 | Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment? ( Boelens, HA; Endtz, HP; Hansen, BE; Kuipers, EJ; Kusters, JG; Ouwedijk, M; Van der Woude, CJ; West, RL, 2005) |
| "Oral doses of norfloxacin (80 mg/kg of body weight per day) and ciprofloxacin (25 and 80 mg/kg/day) and intramuscular doses of teicoplanin (5 mg/kg/day), all administered once a day for 10 days, were evaluated as a means of preventing encrusted cystitis caused by Corynebacterium group D2." | 3.68 | Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats. ( Avilés, P; Castilla, C; Rodriguez-Tudela, JL; Soriano, F, 1991) |
| " Among quinolones, the most active agents are ciprofloxacin and ofloxacin (MIC modes: 4 and 2 mg/l), so these antimicrobials could be used for the treatment of urinary tract infections caused by Corynebacterium group D2." | 3.67 | [Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity]. ( Cancet, B; Clave, D; Didier, J; Henry-Ferry, S; Marty, N, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 2 |
| Shi, X | 1 |
| Zhang, J | 1 |
| Lv, Y | 1 |
| Du, X | 1 |
| ChaoLuMen, Q | 1 |
| Wang, J | 1 |
| Vaidya, A | 1 |
| Sarbajna, T | 1 |
| Kakizaki, H | 1 |
| Takahashi, Y | 1 |
| Fejes, I | 1 |
| Garcia-Hermosa, P | 1 |
| Bodin, A | 1 |
| Sokol-Leszczynska, B | 1 |
| Leszczynski, P | 1 |
| Lachowicz, D | 1 |
| Rostkowska, O | 1 |
| Niemczyk, M | 1 |
| Piecha, T | 1 |
| van Belkum, A | 1 |
| Sawicka-Grzelak, A | 1 |
| Mlynarczyk, G | 1 |
| de Magalhães Rodrigues Martins, CM | 1 |
| Alves, BG | 1 |
| Monteiro, CP | 1 |
| Pinheiro, ESC | 1 |
| Feckinghaus, MA | 1 |
| Paranhos, LG | 1 |
| Dos Santos, MV | 1 |
| Espínola, M | 1 |
| Somodevilla, A | 1 |
| Domingo, D | 1 |
| Alarcón, T | 1 |
| López-Brea, M | 1 |
| Tarr, PE | 1 |
| Stock, F | 1 |
| Cooke, RH | 1 |
| Fedorko, DP | 1 |
| Lucey, DR | 1 |
| West, RL | 1 |
| Van der Woude, CJ | 1 |
| Endtz, HP | 1 |
| Hansen, BE | 1 |
| Ouwedijk, M | 1 |
| Boelens, HA | 1 |
| Kusters, JG | 1 |
| Kuipers, EJ | 1 |
| Gaskin, PR | 1 |
| StJohn, MA | 1 |
| Cave, CT | 1 |
| Clarke, H | 1 |
| Bayston, R | 1 |
| Levett, PN | 1 |
| Bandera, A | 1 |
| Gori, A | 1 |
| Rossi, MC | 1 |
| Degli Esposti, A | 1 |
| Ferrario, G | 1 |
| Marchetti, G | 1 |
| Tocalli, L | 1 |
| Franzetti, F | 1 |
| Sridhar, MS | 1 |
| Sharma, S | 1 |
| Garg, P | 1 |
| Rao, GN | 1 |
| Soriano, F | 2 |
| Rodriguez-Tudela, JL | 2 |
| Castilla, C | 1 |
| Avilés, P | 2 |
| Barnass, S | 1 |
| Holland, K | 1 |
| Tabaqchali, S | 1 |
| Fernández-Roblas, R | 1 |
| Zapardiel, J | 1 |
| Romero, M | 1 |
| Marty, N | 1 |
| Clave, D | 1 |
| Cancet, B | 1 |
| Henry-Ferry, S | 1 |
| Didier, J | 1 |
| Murphy, PG | 1 |
| Ferguson, WP | 1 |
1 review available for ciprofloxacin and Corynebacterium Infections
| Article | Year |
|---|---|
Keratitis Caused by Candida parapsilosis and Subsequent Corynebacterium macginleyi Infection: Case Report and Short Review.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Candida parapsilosis; Candidiasis; Ciprofloxacin; Co | 2020 |
2 trials available for ciprofloxacin and Corynebacterium Infections
| Article | Year |
|---|---|
Noninferiority field trial for evaluation of efficacy of ciprofloxacin associated with internal teat sealant as dry-off protocol.
Topics: Animals; Anti-Bacterial Agents; Bismuth; Brazil; Cattle; Cephalosporins; Ciprofloxacin; Corynebacter | 2019 |
Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment?
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Corynebacterium Infections; Crohn | 2005 |
13 other studies available for ciprofloxacin and Corynebacterium Infections
| Article | Year |
|---|---|
Wide spread and diversity of mutation in the gyrA gene of quinolone-resistant Corynebacterium striatum strains isolated from three tertiary hospitals in China.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacteri | 2021 |
Topics: Administration, Ophthalmic; Administration, Oral; Adult; Aspergillosis; Aspergillus; Ciprofloxacin; | 2020 |
Corynebacterium coyleae as potential urinary tract pathogen.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacteri | 2019 |
[Antibiotic susceptibility of Corynebacterium macginleyi strains causing conjunctivitis].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Conjunctiva; Conjunctivitis; C | 2010 |
Multidrug-resistant Corynebacterium striatum pneumonia in a heart transplant recipient.
Topics: Amphotericin B; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Multipl | 2003 |
Cerebrospinal fluid shunt infection due to Corynebacterium xerosis.
Topics: Ciprofloxacin; Corynebacterium Infections; Drug Resistance, Microbial; Equipment Contamination; Huma | 1994 |
A case of costochondral abscess due to Corynebacterium minutissimum in an HIV-infected patient.
Topics: Abscess; Adult; AIDS-Related Opportunistic Infections; Amikacin; Amoxicillin; Anti-Bacterial Agents; | 2000 |
Epithelial infectious crystalline keratopathy.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Corneal Diseases; Corynebacterium Infections; Epitheliu | 2001 |
Treatment of encrusted cystitis caused by Corynebacterium group D2 with norfloxacin, ciprofloxacin, and teicoplanin in an experimental model in rats.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium Infections; Cystitis; Female; Glycope | 1991 |
Vancomycin-resistant Corynebacterium species causing prosthetic valve endocarditis successfully treated with imipenem and ciprofloxacin.
Topics: Adult; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Microbial; Endoc | 1991 |
Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.
Topics: Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, Microbial; Humans; Norf | 1989 |
[Corynebacterium group D2. Clinical study, biochemical identification and antibiotic sensitivity].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Corynebacterium; Corynebacterium Infections; Drug Resistance, | 1988 |
Corynebacterium jeikeium (group JK) resistance to ciprofloxacin emerging during therapy.
Topics: Adult; Ciprofloxacin; Corynebacterium Infections; Drug Resistance, Microbial; Female; Humans | 1987 |